RESEARCHERS have administered the first UK dose in a phase 3 trial of an investigational mRNA vaccine designed to protect against pandemic influenza strains such as bird flu.
The study will assess the safety and immune response of mRNA-1018, an investigational A(H5) pandemic influenza vaccine candidate from Moderna, targeting influenza viruses that circulate in birds and have pandemic potential.
See also: Avian influenza cases hit 100 as industry urged to maintain year-round vigilance
Around 4,000 adult volunteers aged 18 and over are due to take part in the trial across the UK and the US, with 3,000 of those participants expected to be recruited in the UK. A total of 26 UK sites will administer the vaccine through community clinics in England and Scotland.
The trial is supported by the NIHR and sponsored by Moderna as part of the company’s strategic partnership with the UK government, managed by the UK Health Security Agency. It is also backed through Moderna’s collaboration with the Coalition for Epidemic Preparedness Innovations.
For the poultry sector, the study highlights the continued concern around H5 avian influenza viruses as they circulate in bird populations and spill over into a growing range of mammals. While the virus does not currently spread easily to humans and person-to-person transmission remains rare, the concern is that it could adapt and become more transmissible.
Immune response
According to the trial announcement, 116 confirmed human cases have been recorded worldwide since 2024, with almost all linked to close contact with infected animals.
The study is intended to generate evidence on whether the vaccine can trigger a strong immune response against currently circulating and emerging H5N1 strains, helping inform future pandemic planning.
It also forms part of a broader response to avian influenza. Poultry vaccine trials are already under way in the UK following recent outbreaks.
Dr Rebecca Clark, the trial’s national co-ordinating investigator at Layton Medical Centre in Blackpool, said the H5N1 strain was continuing to evolve and spread across animal species, meaning the risk of future human transmission had to be taken seriously even if it does not currently move easily between people.
The programme is being delivered through the UK Vaccine Innovation Pathway, a clinical trial accelerator designed to speed vaccine study set-up and delivery. Organisers said the first participant was enrolled in less than half the government’s 150-day study set-up target.
Recruitment is being supported through the NIHR’s Be Part of Research service.






